Strategic Collaborations Navigo Proteins has a history of integrating with partners (SCK CEN, VERAXA Biotech, Nostrum Biodiscovery) to advance radiotheranostics, click-chemistry platforms, and affinity ligand technologies, signaling ongoing openness to co-development and off-the-shelf solutions for advanced bioprocessing and targeted therapeutics.

Affilin Platform Core asset Affilin and related precision ligand platforms position Navigo as a supplier of proprietary targeting ligands for chromatography, purification resin development, and GMP-ready manufacturing support, presenting upsell opportunities in custom resin development and process optimization services.

Diversified Use Cases Past initiatives include COVID-19 spike protein affinity resin and ANG1-C4BP fusion protein targeting, indicating broad applicability of their affinity ligands across vaccines, diagnostics, and therapeutic protein purification, suggesting cross-sell into multiple market segments.

Strategic Partnerships Active collaborations with industry players across biotech tools and services imply a willingness to adopt complementary technologies; sales opportunities exist in bundling platforms like Affilin with click chemistry or radiochemical expertise for integrated solutions.

Growth Footprint As a 51-200 employee biotech firm with rising visibility and revenue in the multi-million range, Navigo is scaling partnerships and asset vehicles (Navigo Pure, Navigo Precision), offering a compelling entry for channel partners, co-selling, and OEM-type arrangements to accelerate market reach.